



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated: 19-12-2008

Mr. Munir Ahmed,  
Director (Admn.),  
IPO-Pakistan,  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 13-12-2008 TO BE PUBLISHED 20-12-2008 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

**ENCL:**

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
**Karachi**

No.2/2/2003-F.Sec.

Dated: 19-12-2008

To,

Mr. Manzoor Ahmed  
Section Officer  
Cabinet Secretariat  
Cabinet Division  
Government of Pakistan  
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 13-12-2008 TO BE PUBLISHED 20-12-2008 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23<sup>rd</sup> April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000

	<b><u>11-12-2008</u></b>	
1442/2008	Abbott Laboratories USA (Priority 14-12-08 USA)	“Cyclopropyl amine derivatives”
1443/2008	Novartis AG, Switzerland (Priority 12-12-07 USA)	“Aminothiazoles and their uses”
1444/2008	SanofiAventis Deutschland GmbH Germany (Priority 04-6-02 Germany) <b>Divisional</b>	“A pharmaceutically acceptable salt of a substituted thiophene-derived compound”
1445/2008	1.Syngenta Participations AG, Switzerland 2. Syngenta Limited, United Kingdom (Priority 13-12-07 India)	“Novel herbicides”
	<b><u>12-12-2008</u></b>	
1446/2008	Genyme Corporation, USA (Priority 14-12-07 USA)	“Pharmaceutical compositions”
1447/2008	1.Linde AG Germany 2.Saudi Basic Industries Corporation Saudi Arabia (Priority 12-12-07 Europe)	“Catalyst composition for oligomerization of ethylene, oligomerization process and method for its preparation”
1448/2008	SanofiAventis France (Priority 14-12-07 France)	“Novel process for preparing azetidines derivatives”
1449/2008	1.Kyushu University, National University Corporation 2. Takeda Pharmaceutical Company, Limited.	“Drug-containing nanoparticles”

	Japan (Priority 12-12-07 Japan)	
	<b>13-12-2008</b>	
1450/2008	1. Medarex Inc., 2. Pfizer Inc. USA (Priority 14-12-07 USA)	“Binding molecules to the human ox40 receptor”
1451/2008	Nestec S.A., Switzerland (Priority 14-12-07 Europe)	“Hypoallergenic cereal protein and uses thereof”
1452/2008	1. Dr. Rahila Nazli 2. Javed iqbal 3. Muhammad Laiq, PCSIR, Karachi	“Fabrication of cost-effective mosquito cage to evaluate their life cycle”
1453/2008	Honda Motor Co., Ltd. Japan (Priority 25-12-07 Japan)	“Battery cooling air intake structure”
1454/2008	Merck & Co., Inc. USA (Priority 05-10-05 USA) <b>Divisional</b>	“A pharmaceutically acceptable salt of a substituted 2-azetidinone compound”
1455/2008	Novartis AG, Switzerland (Priority 14-12-07 USA)	“Kinesin inhibitors as cancer therapeutics”
1456/2008	H. Lundbeck A/S. Denmark (Priority 14-12-07 Denmark)	“4-[2,3-difluoro-6-(2-fluoro-4- methyl-phenylsulfanyl)-piperidine”
1457/2008	1. H. Lundbeck A/S. Denmark 2. Takeda Pharmaceuticals North America Inc. USA (Priority 14-12-07 Denmark)	“Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter”
1458/2008	Intervet International B.V., The Netherlands (Priority 17-12-07 USA)	“Anthelmintic agents and their use”

## SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139545	Wyeth. USA	234/1997
139546	Glaxo Group Limited., Great Britain	226/1998
139547	Agouron Pharmaceuticals, Inc., USA	666/2000
139548	AstraZeneca AB., Sweden	708/2000
139549	Boehringer Ingelheim Pharmaceuticals Inc., USA	227/2004
139550	Maschinenfabrik Rieter AG., Schweiz	678/2005
139551	Pai Lung Machinery Mill Co., Limited. Taiwan, R.O.C.	811/2005
139552	Pai Lung Machinery Mill Co., Limited. Taiwan, R.O.C.	812/2005
139553	1.Mr. Kamran Hafeez. 2.Mr. Ikram-e-Khuda. 3.Mr. Arif Karim. 4.Mr. Fausak Ghazanfar. 5.Mr. Dr. Muhammad Yaqub. PCSIR. Karachi	908/2005
139554	1.Faisal Ghazanfar. 2.Arif Karim. 3.Ikran-e-Khuda. 4.Kamran Hafeez. 5.Dr.Muhammad Yaqub. PCSIR, Karachi	909/2005
139555	Otsuka Pharmaceutical Factory, Inc. Japan	994/2005

139556	Teijin Twaron B.V. Netherlands	1002/2005
139557	Wyeth. USA	910/2006
139558	Agouron Pharmaceuticals, Inc., USA	1731/2006
139559	AstraZeneca AB. Sweden	1067/2007

**(MRS. YASMEEN ABBASI)**  
**CONTROLLER OF PATENTS**  
Tel: 9215488